Abstract
Recommendations on the use of MF59-Adjuvanted Trivalent Influenza Vaccine (Fluad®): Supplemental Statement of Seasonal Influenza Vaccine for 2011-2012 An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)†.
Highlights
In February 2011, Fluad® (Novartis), a trivalent inactivated subunit influenza vaccine (TIV) adjuvanted with MF59C.11 was authorized in Canada for use in adults 65 years of age and older for active immunization against influenza caused by specific strains of influenza virus contained in the vaccine
Vaccination effectiveness: Overall: OR 2.16, 95% CI 1.56-2.98) Fluad®: 94% (47-100%) Agrippal S1®: 24.5% (0-45%)
Cases: Consecutive non-institutionalized elderly living in hospital catchment area for previous 6 months, and admitted for emergency hospitalization between Nov 2004 and Mar 2005 acute coronary syndrome (ACS), cerebrovascular accidents (CVA) or pneumonia
Summary
In February 2011, Fluad® (Novartis), a trivalent inactivated subunit influenza vaccine (TIV) adjuvanted with MF59C.11 was authorized in Canada for use in adults 65 years of age and older for active immunization against influenza caused by specific strains of influenza virus contained in the vaccine. It is the first seasonal influenza vaccine in Canada to contain an adjuvant and will be used in the upcoming fall 2011 influenza season. Fluad® has been licensed and used extensively in Europe for adults 65 years and older since 1997 This supplement to the National Advisory Committee on Immunization (NACI) statement on seasonal TIV for 2011-12 will:. At this time, NACI concludes there is insufficient evidence to make a recommendation for the preferential use of Fluad® over other TIV products currently authorized for use in Canada. (NACI Recommendation Grade I)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
